New combo therapy before surgery shows promise for bile duct cancer

NCT ID NCT07639528

Not yet recruiting Disease control Sponsor: Northwestern University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether giving a mix of immunotherapy (durvalumab), chemotherapy (cisplatin and gemcitabine), and possibly a targeted drug (futibatinib) before surgery can improve outcomes for patients with resectable intrahepatic cholangiocarcinoma, a type of bile duct cancer. About 44 participants will receive treatment based on their tumor's genetic profile. The goal is to see if this approach makes surgery more effective and helps prevent the cancer from coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab, cisplatin, gemcitabine, futibatinib
What this could lead to: If successful, this approach could shrink tumors before surgery and reduce the chance of cancer returning in patients with intrahepatic cholangiocarcinoma.
What could go wrong: This is an early-phase trial with only 44 participants, so results may not apply to all patients. The combination therapy may cause significant side effects, and not all patients may complete treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates